Cargando…

Optimized vaccine candidate MVA-S(3P) fully protects against SARS-CoV-2 infection in hamsters

The development of novel optimized vaccines against coronavirus disease 2019 (COVID-19) that are capable of controlling the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic and the appearance of different variants of concern (VoC) is needed to fully prevent the transmission of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdelnabi, Rana, Pérez, Patricia, Astorgano, David, Albericio, Guillermo, Kerstens, Winnie, Thibaut, Hendrik Jan, Coelmont, Lotte, Weynand, Birgit, Labiod, Nuria, Delgado, Rafael, Montenegro, Dolores, Puentes, Eugenia, Rodríguez, Esteban, Neyts, Johan, Dallmeier, Kai, Esteban, Mariano, García-Arriaza, Juan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619667/
https://www.ncbi.nlm.nih.gov/pubmed/37920464
http://dx.doi.org/10.3389/fimmu.2023.1163159
_version_ 1785130035761381376
author Abdelnabi, Rana
Pérez, Patricia
Astorgano, David
Albericio, Guillermo
Kerstens, Winnie
Thibaut, Hendrik Jan
Coelmont, Lotte
Weynand, Birgit
Labiod, Nuria
Delgado, Rafael
Montenegro, Dolores
Puentes, Eugenia
Rodríguez, Esteban
Neyts, Johan
Dallmeier, Kai
Esteban, Mariano
García-Arriaza, Juan
author_facet Abdelnabi, Rana
Pérez, Patricia
Astorgano, David
Albericio, Guillermo
Kerstens, Winnie
Thibaut, Hendrik Jan
Coelmont, Lotte
Weynand, Birgit
Labiod, Nuria
Delgado, Rafael
Montenegro, Dolores
Puentes, Eugenia
Rodríguez, Esteban
Neyts, Johan
Dallmeier, Kai
Esteban, Mariano
García-Arriaza, Juan
author_sort Abdelnabi, Rana
collection PubMed
description The development of novel optimized vaccines against coronavirus disease 2019 (COVID-19) that are capable of controlling the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic and the appearance of different variants of concern (VoC) is needed to fully prevent the transmission of the virus. In the present study, we describe the enhanced immunogenicity and efficacy elicited in hamsters by a modified vaccinia virus Ankara (MVA) vector expressing a full-length prefusion-stabilized SARS-CoV-2 spike (S) protein [termed MVA–S(3P)]. Hamsters vaccinated with one or two doses of MVA-S(3P) developed high titers of S-binding IgG antibodies and neutralizing antibodies against the ancestral Wuhan SARS-CoV-2 virus and VoC beta, gamma, and delta, as well as against omicron, although with a somewhat lower neutralization activity. After SARS-CoV-2 challenge, vaccinated hamsters did not lose body weight as compared to matched placebo (MVA-WT) controls. Consistently, vaccinated hamsters exhibited significantly reduced viral RNA in the lungs and nasal washes, and no infectious virus was detected in the lungs in comparison to controls. Furthermore, almost no lung histopathology was detected in MVA-S(3P)-vaccinated hamsters, which also showed significantly reduced levels of proinflammatory cytokines in the lungs compared to unvaccinated hamsters. These results reinforce the use of MVA-S(3P) as a vaccine candidate against COVID-19 in clinical trials.
format Online
Article
Text
id pubmed-10619667
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-106196672023-11-02 Optimized vaccine candidate MVA-S(3P) fully protects against SARS-CoV-2 infection in hamsters Abdelnabi, Rana Pérez, Patricia Astorgano, David Albericio, Guillermo Kerstens, Winnie Thibaut, Hendrik Jan Coelmont, Lotte Weynand, Birgit Labiod, Nuria Delgado, Rafael Montenegro, Dolores Puentes, Eugenia Rodríguez, Esteban Neyts, Johan Dallmeier, Kai Esteban, Mariano García-Arriaza, Juan Front Immunol Immunology The development of novel optimized vaccines against coronavirus disease 2019 (COVID-19) that are capable of controlling the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic and the appearance of different variants of concern (VoC) is needed to fully prevent the transmission of the virus. In the present study, we describe the enhanced immunogenicity and efficacy elicited in hamsters by a modified vaccinia virus Ankara (MVA) vector expressing a full-length prefusion-stabilized SARS-CoV-2 spike (S) protein [termed MVA–S(3P)]. Hamsters vaccinated with one or two doses of MVA-S(3P) developed high titers of S-binding IgG antibodies and neutralizing antibodies against the ancestral Wuhan SARS-CoV-2 virus and VoC beta, gamma, and delta, as well as against omicron, although with a somewhat lower neutralization activity. After SARS-CoV-2 challenge, vaccinated hamsters did not lose body weight as compared to matched placebo (MVA-WT) controls. Consistently, vaccinated hamsters exhibited significantly reduced viral RNA in the lungs and nasal washes, and no infectious virus was detected in the lungs in comparison to controls. Furthermore, almost no lung histopathology was detected in MVA-S(3P)-vaccinated hamsters, which also showed significantly reduced levels of proinflammatory cytokines in the lungs compared to unvaccinated hamsters. These results reinforce the use of MVA-S(3P) as a vaccine candidate against COVID-19 in clinical trials. Frontiers Media S.A. 2023-10-18 /pmc/articles/PMC10619667/ /pubmed/37920464 http://dx.doi.org/10.3389/fimmu.2023.1163159 Text en Copyright © 2023 Abdelnabi, Pérez, Astorgano, Albericio, Kerstens, Thibaut, Coelmont, Weynand, Labiod, Delgado, Montenegro, Puentes, Rodríguez, Neyts, Dallmeier, Esteban and García-Arriaza https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Abdelnabi, Rana
Pérez, Patricia
Astorgano, David
Albericio, Guillermo
Kerstens, Winnie
Thibaut, Hendrik Jan
Coelmont, Lotte
Weynand, Birgit
Labiod, Nuria
Delgado, Rafael
Montenegro, Dolores
Puentes, Eugenia
Rodríguez, Esteban
Neyts, Johan
Dallmeier, Kai
Esteban, Mariano
García-Arriaza, Juan
Optimized vaccine candidate MVA-S(3P) fully protects against SARS-CoV-2 infection in hamsters
title Optimized vaccine candidate MVA-S(3P) fully protects against SARS-CoV-2 infection in hamsters
title_full Optimized vaccine candidate MVA-S(3P) fully protects against SARS-CoV-2 infection in hamsters
title_fullStr Optimized vaccine candidate MVA-S(3P) fully protects against SARS-CoV-2 infection in hamsters
title_full_unstemmed Optimized vaccine candidate MVA-S(3P) fully protects against SARS-CoV-2 infection in hamsters
title_short Optimized vaccine candidate MVA-S(3P) fully protects against SARS-CoV-2 infection in hamsters
title_sort optimized vaccine candidate mva-s(3p) fully protects against sars-cov-2 infection in hamsters
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619667/
https://www.ncbi.nlm.nih.gov/pubmed/37920464
http://dx.doi.org/10.3389/fimmu.2023.1163159
work_keys_str_mv AT abdelnabirana optimizedvaccinecandidatemvas3pfullyprotectsagainstsarscov2infectioninhamsters
AT perezpatricia optimizedvaccinecandidatemvas3pfullyprotectsagainstsarscov2infectioninhamsters
AT astorganodavid optimizedvaccinecandidatemvas3pfullyprotectsagainstsarscov2infectioninhamsters
AT albericioguillermo optimizedvaccinecandidatemvas3pfullyprotectsagainstsarscov2infectioninhamsters
AT kerstenswinnie optimizedvaccinecandidatemvas3pfullyprotectsagainstsarscov2infectioninhamsters
AT thibauthendrikjan optimizedvaccinecandidatemvas3pfullyprotectsagainstsarscov2infectioninhamsters
AT coelmontlotte optimizedvaccinecandidatemvas3pfullyprotectsagainstsarscov2infectioninhamsters
AT weynandbirgit optimizedvaccinecandidatemvas3pfullyprotectsagainstsarscov2infectioninhamsters
AT labiodnuria optimizedvaccinecandidatemvas3pfullyprotectsagainstsarscov2infectioninhamsters
AT delgadorafael optimizedvaccinecandidatemvas3pfullyprotectsagainstsarscov2infectioninhamsters
AT montenegrodolores optimizedvaccinecandidatemvas3pfullyprotectsagainstsarscov2infectioninhamsters
AT puenteseugenia optimizedvaccinecandidatemvas3pfullyprotectsagainstsarscov2infectioninhamsters
AT rodriguezesteban optimizedvaccinecandidatemvas3pfullyprotectsagainstsarscov2infectioninhamsters
AT neytsjohan optimizedvaccinecandidatemvas3pfullyprotectsagainstsarscov2infectioninhamsters
AT dallmeierkai optimizedvaccinecandidatemvas3pfullyprotectsagainstsarscov2infectioninhamsters
AT estebanmariano optimizedvaccinecandidatemvas3pfullyprotectsagainstsarscov2infectioninhamsters
AT garciaarriazajuan optimizedvaccinecandidatemvas3pfullyprotectsagainstsarscov2infectioninhamsters